Varda Space Raises $251M

Varda Space Industries has raised $251 million in series D funding, bringing its total funding to $598 million, and is now valued at $1.6 billion. The company plans to use the funding to accelerate operations of its W-Series spacecraft.

Varda Space Industries announced on September 30 that it raised $251 million in series D funding, led by Lux Capital and Natural Capital. The funding brings the company's total funding to $598 million.

The company is now valued at $1.6 billion, according to Delian Asparouhov, Varda's co-founder and President. Asparouhov said the funding will be used to accelerate operations of its W-Series spacecraft.

Varda has completed six launch and re-entry missions and has scheduled more than a dozen launches through the end of 2028. The company builds small laboratories that launch into space with a pharmaceutical component as their payload.

The laboratories allow microgravity to crystallize the ingredient in space, a process long studied aboard the International Space Station. Varda's co-founder and CEO, Will Bruey, is a former Space Exploration Technologies Corp. engineer.

Lux Capital partner Shanin Farshchi said in-space manufacturing means building what space needs, in space, and making what Earth can't. Varda plans to use the funding to increase its cadence and deepen its pharmaceutical partnerships.

The company was co-founded in 2021 by Asparouhov and Bruey. Varda is among a small group of US companies developing fleets of uncrewed space capsules designed to serve as orbital laboratories and manufacturing facilities.

Varda's valuation and funding are a significant milestone for the company, which is working towards delivering the first medicine made in space. The company's W-Series spacecraft is designed to launch payloads into space and return them to Earth.

Key facts

  • Varda Space Industries raised $251 million in series D funding
  • The company is now valued at $1.6 billion
  • Varda has completed six launch and re-entry missions
  • The company has scheduled more than a dozen launches through the end of 2028

Three perspectives

Neutral

Varda Space Industries' funding and valuation are a significant development for the company and the space industry. The company's plans to accelerate operations and deepen pharmaceutical partnerships will be closely watched. Varda's success will depend on its ability to deliver on its promises and handle the challenges of in-space manufacturing.

Positive

Varda Space Industries' funding and valuation are a major milestone for the company and a significant step forward for the space industry. The company's plans to increase its cadence and deepen its pharmaceutical partnerships are a positive development for the industry. Varda's success could lead to the development of new medicines and treatments.

Negative

Varda Space Industries' funding and valuation may not be enough to guarantee the company's success. The company faces significant challenges in the development of its W-Series spacecraft and the delivery of its promises. Varda's success will depend on its ability to overcome these challenges and handle the risks of in-space manufacturing.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

All sections

Edition